Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin

PRESS RELEASE Iconovo expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting…

Iconovo uppdaterar sina långsiktiga finansiella mål – ser stark intäktsökning med hög marginal

PRESSMEDDELANDE Iconovo tillkännager idag sina femårsmål för verksamheten. År 2027 räknar bolaget med att uppnå en försäljning om 250 miljoner…

Interim Report for Q1 2022 available in English

The abbreviated Interim Report for January to March 2022 is now avaialble in English. Read it here

Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products

Iconovo has entered into a strategic collaboration with Galenica AB – a company specializing in the development and manufacture of pharmaceuticals…

Quarterly Report for Q1 2022 released

The Quarterly Report for Q1 2022 was released today and is available here, in Swedish.

Meet Iconovo at RDD, Orlando

A team from Iconovo will visit RDD, Respiratory Drug Delivery in beginning of May, in Orlando. There will be an exhibition from Iconovo with inhalation…